吡格列酮用于卒中合并糖尿病前期患者的治疗:IRIS随机临床试验的事后分析
该事后分析基于IRIS随机临床试验,纳入2885例有卒中或短暂性脑缺血发作且存在胰岛素抵抗但无糖尿病的患者,评估吡格列酮在糖尿病前期患者中的疗效。结果显示,在依从性良好者中,吡格列酮显著降低卒中/心肌梗死、卒中、急性冠脉综合征、卒中/心肌梗死/心力衰竭住院及进展为糖尿病的风险,意向性治疗分析也显示显著降低但程度较轻。
要点
- 意向性治疗分析中获益仍显著,但幅度较小。
核心结论
- 吡格列酮可能对卒中/短暂性脑缺血发作合并糖尿病前期患者的二级预防有效,尤其在依从性良好者中。
研究设计与样本
- IRIS试验为随机多中心临床试验,纳入既往卒中或短暂性脑缺血发作且存在胰岛素抵抗但无糖尿病的患者。
- 本分析纳入2885例患者(吡格列酮组1456例,安慰剂组1429例),中位随访4.8年。
- 吡格列酮起始15 mg,剂量滴定至目标45 mg每日,或匹配安慰剂。
主要发现
- 依从性良好的糖尿病前期患者中,卒中/心肌梗死HR 0.57(95%CI 0.39-0.84),卒中HR 0.64(95%CI 0.42-0.99)。
- 依从性良好的糖尿病前期患者中,急性冠脉综合征HR 0.47(95%CI 0.26-0.85),卒中/心肌梗死/心力衰竭住院HR 0.61(95%CI 0.42-0.88)。
- 依从性良好的糖尿病前期患者中,进展为糖尿病HR 0.18(95%CI 0.10-0.33)。
- 意向性治疗分析中,卒中/心肌梗死HR 0.70(95%CI 0.56-0.88),卒中HR 0.72(95%CI 0.56-0.92)。
- 意向性治疗分析中,急性冠脉综合征HR 0.72(95%CI 0.52-1.00),卒中/心肌梗死/心力衰竭住院HR 0.78(95%CI 0.63-0.96),进展为糖尿病HR 0.46(95%CI 0.35-0.61)。
关键数值与推荐
- 糖尿病前期定义为糖化血红蛋白5.7%至6.4%或空腹血糖100 mg/dL至125 mg/dL。
- 良好依从性定义为服用方案剂量的80%或以上。
临床怎么用
- 对于卒中或短暂性脑缺血发作合并糖尿病前期的患者,可考虑使用吡格列酮进行二级预防。
- 需关注吡格列酮的体重增加、水肿及严重骨折风险轻微增加等不良反应。
局限性
- 本研究为事后分析,结果需谨慎解读。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In the Insulin Resistance Intervention After Stroke (IRIS) randomized clinical trial, pioglitazone, an insulin-sensitizing agent, reduced the risk for recurrent stroke or myocardial infarction (MI) among patients with insulin resistance. However, insulin resistance is not commonly measured in clinical practice. OBJECTIVE: To analyze the effects of pioglitazone in patients with good adherence as well as intention-to-treat effects of pioglitazone in patients with prediabetes in the IRIS trial. DESIGN, SETTING, AND PARTICIPANTS: The IRIS trial was a randomized multicenter clinical trial in patients with prior stroke or transient ischemic attack as well as insulin resistance but not diabetes. Patients were enrolled from February 2005 to January 2013, and the median follow-up was 4.8 years. The post hoc analyses reported here were performed from June to September 2018. Per American Diabetes Association criteria, prediabetes was defined as having a hemoglobin A1c level of 5.7% to 6.4% or fasting plasma glucose level of 100 mg/dL to 125 mg/dL (to convert to mmol/L, multiply by 0.0555). Good adherence was defined as taking 80% or more of the protocol dose. Fasting glucose and hemoglobin A1c, used to define prediabetes, and adherence of 80% or higher, stipulated in the protocol as defining good adherence, were prespecified subgroups in the analysis plan. INTERVENTIONS: Participants were randomized to 15 mg of pioglitazone, with dose titrated to target of 45 mg daily, or matching placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was recurrent stroke or MI. Secondary outcomes included stroke, acute coronary syndrome, stroke/MI/hospitalization for heart failure, and progression to diabetes. RESULTS: Among 3876 participants analyzed in the IRIS trial, 2885 were included in this analysis (1456 in the pioglitazone cohort and 1429 in the placebo cohort). The mean (SD) age of patients was 64 (11) years, and 974 (66.9%) and 908 (63.5%) of patients were men in the pioglitazone and placebo cohort, respectively. In the prediabetic population with good adherence (644 of 1456 individuals [44.2%] in the pioglitazone group and 810 of 1429 [56.7%] in the placebo group), the hazard ratios (95% CI) were 0.57 (0.39-0.84) for stroke/MI, 0.64 (0.42-0.99) for stroke, 0.47 (0.26-0.85) for acute coronary syndrome, 0.61 (0.42-0.88) for stroke/MI/hospitalization for heart failure, and 0.18 (0.10-0.33) for progression to diabetes. There was a nonsignificant reduction in overall mortality, cancer, and hospitalization, a slight increase in serious bone fractures, and an increase in weight gain and edema. Intention-to-treat results also showed significant reduction of events but to a lesser degree. Hazard ratios (95% CI) were 0.70 (0.56-0.88) for stroke/MI, 0.72 (0.56-0.92) for stroke, 0.72 (0.52-1.00) for acute coronary syndrome, 0.78 (0.63-0.96), for stroke/MI/hospitalization for heart failure, and 0.46 (0.35 to 0.61) for progression to diabetes. CONCLUSIONS AND RELEVANCE: Pioglitazone may be effective for secondary prevention in patients with stroke/transient ischemic attack and with prediabetes, particularly in those with good adherence. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00091949.
引用
- Spence JD, Viscoli CM, Inzucchi SE, et al. Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. JAMA Neurol. 2019. PMID: 30734043. doi:10.1001/jamaneurol.2019.0079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。